This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The stakes are high in pharmacy settings, where miscommunication can directly impact patientcare. Regular performance reviews, goal-setting, and clear documentation aren't just administrative tasks—they're critical shields against potential workplace conflicts and legal challenges. Subscribe Now!
Positive results have been announced from a phase 3 clinical trial evaluating the efficacy and safety of deucravacitinib (Sotyktu) for the treatment of active psoriatic arthritis (PsA) in adult patients who are naïve to biologic disease-modifying anti-rheumatic medications, Bristol Myers Squibb announced in a release. June 11, 2025.
Despite a high prevalence of childhood and youth-aged obesity, the use of medications for treating obesity is persistently low among children and young adults (YA), according to an abstract presented at the American Diabetes Association’s 85th Scientific Sessions, held in Chicago, Illinois, from June 20-23, 2025. Accessed June 25, 2025.
The patients that are being kicked out of Rite Aid to find pharmacies have prescriptions and insurance that lose money and pharmacies are reluctant to them take on. Once the 351 Rite Aid pharmacies in Pennsylvania finally close in 2025, that will be over 600 pharmacies in Pennsylvania that closed in the last 2 years.
RPM’s Booming Promise and Its Perils Remote patient monitoring (RPM) is not just a trend but a core pillar of modern US healthcare. By 2025, over 71 million Americans (26% of the population) are expected to use RPM services, with the US market projected to double to $29+ billion by 2030. 2025, April). 2024, September).
This guest blog is one in a series by sponsors of the 2025 PQA Annual Meeting on unlocking clinical revenue from within pharmacy workflow. While clinical services represent the future, the practical challenge of documenting these encounters threatens to impede progress. The business of pharmacy is at a critical juncture.
Development and collaboration in oncology pharmacy An emerging opportunity lies in the integration of advanced technologies such as precision medicine and artificial intelligence (AI) to optimise patientcare. On a global scale, Netty believes the growing use of biosimilars presents a significant opportunity to improve patientcare.
As a first step, the PQA Blueprint 2025 was leveraged to shape efforts, and objectives, strategies, and tactics were developed to strategically support success of the MTM initiative. 1-2 years) Increase standardized HIT for documentation of MTM services Re-establish consensus on standards for clinical documentation for MTM services (e.g.,
Pharmacists are essential in managing access, patient education, and monitoring outcomes, ensuring adherence and addressing administrative challenges. SHOW MORE Discover how Vyepti revolutionizes migraine prevention with rapid efficacy and strong safety, empowering pharmacists to enhance patientcare. Accessed July 2, 2025.
The FDA has approved sebetralstat (Ekterly) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age or older, according to a release from KalVista Pharmaceuticals. Patients received either 300 mg or 600 mg sebetralstat or placebo. July 7, 2025. Accessed July 7, 2025.
While the European Medicines Agency mandated pre-treatment DPD testing in Europe as early as 2020, and the UK’s National Health Service followed suit the same year, the US only reached a consensus in 2025. Accessed July 21, 2025. NHS gives cancer patients genetic test to select best treatment. Accessed July 21, 2025.
TCSs are the first-line anti-inflammatory treatment and their effectiveness and safety have been well documented.” However, regarding the strength, quantity, and duration of use recommended for these drugs, opinions vary among HCPs and patients. Accessed July 8, 2025. image credit: jittawit.21 References 1. Aust Prescr.
5 Despite these advancements in treatment options, the management of PsD remains a challenge for providers looking to improve their patients’ QOL. This led researchers to explore a specific region of the world in order to better documentpatients’ understanding of the disease. Accessed June 11, 2025. References 1.
Throughout my practicum, I engaged in conversations related to MTM services and how the patientcare process across pharmacy practice lacks uniformity, which makes it challenging to develop patient-centered outcome measures. It is clear to me that this rational approach is vital for practice standardization and documentation.
The properties of thimerosal were documented to contribute to the safe use of multidose vials and packaging of vaccines, such as seasonal and pandemic influenza vaccines. 2 Currently, there are 3 FDA-approved seasonal influenza vaccines that contain a concentration of mercury, as evident from January 15, 2025, on the CDC website.
Geison’s findings, which draw on Pasteur’s previously inaccessible laboratory notebooks, offer detailed documentation of how public scientific claims may be shaped by selective presentation of data. This has practical consequences for patientcare, policy development, and the evaluation of novel interventions.
By 2025, healthcare data is projected to grow at an annual rate of 36% - outpacing industries like manufacturing, financial services, and media by as much as 11%. Informed decision-making requires evidence grounded in scientifically validated methodologies, whether for clinical development, regulatory approval, or patientcare.
The landscape of CMS Transitional Care Management (TCM) billing and compliance updates for 2025 is at a pivotal juncture. For healthcare executives, providers, and payers, mastering these requirements is not only essential for compliance but also for driving measurable improvements in patient outcomes and financial sustainability.
The ultimate guide to 2025 healthcare and life sciences conferences Stay ahead of the latest developments and networking opportunities in the health and life sciences sector with Fulds 2025 Health & Life Sciences Conference Directory. Whats inside?
As a first step, the PQA Blueprint 2025 was leveraged to shape efforts, and objectives, strategies, and tactics were developed to strategically support success of the MTM initiative. 1-2 years) Increase standardized HIT for documentation of MTM services Re-establish consensus on standards for clinical documentation for MTM services (e.g.,
Cost highlighted progress towards completion of PQA’s strategic plan, Blueprint PQA 2025. The 2024 PQA Annual Report documents our progress towards the plan’s goals. “Goal two of our strategic plan is to advance the quality of pharmacist-provided care and services that optimize medication use, adherence and safety.
We continue to play a central role in driving meaningful improvements and positive changes related to medication safety, adherence and appropriate use.The 2023 PQA Annual Report documents our progress towards Blueprint PQA 2025. There are still numerous opportunities to be involved with PQA and impact quality medication use in 2023.
As a first step, the PQA Blueprint 2025 was leveraged to shape efforts, and objectives, strategies, and tactics were developed to strategically support success of the MTM initiative. Participation in the group is open to any individual at a PQA member organization.
According to the announcement, enabling patients to access medical devices beyond traditional clinical settings can help close the healthcare gap by delivering care “directly to patients, wherever they are – at home, at work, in cities, in rural communities.” We previously blogged on the draft guidance here.
Ultimately, the benefits that clinical supervision bring can contribute to improved patientcare and enhancement of staff morale,’ Ms Mackenzie said. Think about history taking, basic physical examination, documentation, communication… these things haven’t changed, really, for decades.
The most recent CARB addresses the years 2020-2025, building upon the initial one released in 2015. An important accompanying document for Joint Commission standards are Critical Access Hospital Accreditation Survey Activity Guide, for which the January 2023 guide can be found here.
According to the Deloitte report , the volume of health data rose by 40% between 2010 and 2020 and is predicted to climb even higher by 23% by 2025. Merge health data management systems Patientcare needs to be holistic, meaning all healthcare providers should work together to deliver the best possible outcomes.
Digital health is transforming the health care landscape through new technologies and platforms in patientcare management, conducting of clinical trials, patient data collection, and the diagnosis and treatment of disease. Global Strategy on Digital Health 2020-2025.” Ryan Hoshi. James Wabby. 1 November 2022.
Digital health is transforming the health care landscape through new technologies and platforms in patientcare management, conducting of clinical trials, patient data collection, and the diagnosis and treatment of disease. Global Strategy on Digital Health 2020-2025.” Ryan Hoshi. James Wabby. 1 November 2022.
She indicated the requirements went out for comments and expects the group to finalize the document by early next year. He also shared that the three 2022 – 2025 priorities are: Promote a modern and diverse workforce, Enhance organizational agility and resilience, and. Advance health equity. Covid-19 Impact.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content